SBIO Price Forecast & ETF Analysis. Dividend · Expense Ratio · Holdings · NAV · RSI · MACD | US Stocks Today
Nov 11 at 4:00 PM ET (Korea 11/12 06:00)AI-drawn chart patterns are for reference only.
Full metrics table
| Category | US Equities - Industry Sector | Expense | 0.5% | Return% 1Y | 30.48% | Total Holdings | 104 | Perf Week | 4.32% | Volume | 11,179 |
| Asset Type | Equities (Stocks) | AUM | $193M | Return% 3Y | 31.7% | NAV | $57.51 | Perf Month | 12.74% | Avg Volume | 0.04M |
| ETF Type | US Equities | Dividend TTM | - | Return% 5Y | 4.44% | 52W High | -17.83% | Perf Quarter | -13% | Rel Volume | 0.3 |
| Active/Passive | Passive | Div Gr. 3/5Y | - | Return% 10Y | 11.1% | 52W Low | 31.51% | Perf Half Y | 4.49% | Prev Close | $57.58 |
| IPO | 2014/12/31 | Flows% 1M | -3.42% | Return% SI | 8.09% | RSI (14) | 57.35 | Perf YTD | 13.67% | Price | $58.22 |
| Beta | 0.78 | Flows% 3M | 4.96% | Flows% YTD | 41.85% | Flows% 1Y | 81.7% | Perf Year | 26.37% | Volatility(W/M) | 3.69% 3.12% |
| SMA20 | 6.47% | SMA50 | 0.75% | SMA200 | 1.82% | ATR | 1.79 | ||||
ALPS Medical Breakthroughs ETF seeks investment results that correspond (before fees and expenses) generally to the performance of its underlying index, the S-Network Medical Breakthroughs Index. The fund employs a "passive management" - or indexing - investment approach designed to track the performance of the underlying index. It will normally invest at least 80% of its net assets in securities that comprise the underlying index. The underlying index is comprised of small and mid-cap stocks of biotechnology companies that have one or more drugs in either Phase II or Phase III of the U.S. Food and Drug Administration clinical trials.
The top 10 make up 31% of the fund
CRNX Crinetics Pharmaceuticals Inc 4.60% 2 
APGE Apogee Therapeutics Inc 4.29% 3 
CGON Cg Oncology Inc 3.41% 4 
TVTX Travere Therapeutics Inc 3.16% 5 
XENE Xenon Pharmaceuticals Inc 2.99% 6 
DNTH Dianthus Therapeutics Inc 2.96% 7 
ORKA Oruka Therapeutics Inc 2.87% 8 
ACAD Acadia Pharmaceuticals Inc 2.54% 9 
EWTX Edgewise Therapeutics Inc 2.31% 10 
DFTX Definium Therapeutics Inc 2.23% Largest sectors first.
Over the past 1 year, roughly in the middle
18% below its 1-year high.
Traded less than usual. That is 30% of its average volume.
Holding long would have paid off
Bought 5 years ago, your return today would be +25.6%. The S&P 500 did +64% over the same period.
Tap to view numbers
The price swings a lot
At its worst (February 2021) it fell 63% and took 972 days to recover.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Money keeps flowing in
Over the past year, new money equal to 81.7% of assets came in.
Tap to view numbers
CURE Direxion Daily Healthcare Bull 3X ETF 213M 
RXL ProShares Ultra Health Care 2X Shares 118M 
XLVI State Street Health Care Select Sector SPDR Premium Income ETF 40M 
TBXU Direxion Daily Biotech Top 5 Bull 2X ETF 4M 
RXD-1× ProShares UltraShort Health Care -2x Shares 3M 
XLV State Street Health Care Select Sector SPDR ETF 0.08% 
VHT Vanguard Health Care ETF 0.09% 
XBI State Street SPDR S&P Biotech ETF 0.35% 
IYH iShares U.S. Healthcare ETF 0.37% 
FHLC Fidelity MSCI Health Care Index ETF 0.08% 
SCHH Schwab U.S. REIT ETF 0.07% 
XLK State Street Technology Select Sector SPDR ETF 0.08% 
XLF State Street Financial Select Sector SPDR ETF 0.08% 
